L-Sepiapterin provided the strongest and most sustained restoration of BH4 and eNOS activity, whereas CDDO-Me was effective primarily at early time points; both agents consistently reduced iNOS induction, highlighting their relative efficacy in correcting infection-induced endothelial dysfunction. The gene discussed is NOS2; the disease is endothelial dysfunction.